GCM
AMPH icon

Gladius Capital Management’s Amphastar Pharmaceuticals AMPH Stock Holding History

Gladius Capital Management’s Portfolio AMPH Stock Details AMPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-648
Closed -$28.5K – 304
2024
Q1 		$28.5K Buy
+648
New +$33.5K 0.01% 297
2022
Q3 		– Sell
-997
Closed -$35K – 369
2022
Q2 		$35K Buy
+997
New +$35.6K ﹤0.01% 289

Other funds holding AMPH

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
TD Asset Management
TD Asset Management Toronto, Ontario, Canada $115B AUM 41.58% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $150B AUM 40.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Fuller & Thaler Asset Management
Fuller & Thaler Asset Management San Mateo, California $36.7B AUM 74.15% 1-Year Est. Return
EIP
Epoch Investment Partners New York $17.6B AUM 34.17% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Gladius Capital Management's AMPH Position: Q2 2024 in Review

Gladius Capital Management sold out of Amphastar Pharmaceuticals (AMPH) in Q2 2024, closing a stake of 648 shares — an estimated $28.5K sold.

Gladius Capital Management first reported a position in AMPH in Q2 2022 and held it in 2 quarters. The position peaked at $35K in Q2 2022. 269 funds tracked by Wall St. Rank hold AMPH as of Q2 2024.

  • Gladius Capital Management reported no remaining Amphastar Pharmaceuticals position as of Q2 2024 after selling out during the quarter.
  • Gladius Capital Management sold 648 Amphastar Pharmaceuticals shares in Q2 2024, an estimated $28.5K.
  • Gladius Capital Management first reported a position in Amphastar Pharmaceuticals in Q2 2022 and held it in 2 quarters.
  • Gladius Capital Management's Amphastar Pharmaceuticals position peaked at $35K in Q2 2022.
  • 269 funds tracked by Wall St. Rank held Amphastar Pharmaceuticals as of Q2 2024.

Based on Gladius Capital Management's 13F filing for Q2 2024, filed 18 Jul 2024.